| Serial Number | 90848313 |
| Word Mark | SIERRA ONCOLOGY |
| Filing Date | Monday, July 26, 2021 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, March 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 6, 2022 |
| Goods and Services | Biological and chemical preparations for the treatment of cancer; pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and disorders; pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation; pharmaceutical preparations for use in the prevention and treatment of dermatology, oncology, hematology and for gastroenterological disorders but specifically excluding biological eye tissue, corneas, and other ocular or eye-related human tissue intended for subsequent tissue and organ implantation |
| Goods and Services | Medical services; medical services for the treatment of cancer; medical analysis services for the diagnosis and treatment of patients and persons; medical analysis services for the diagnosis of cancer; providing cancer screening services; providing a website via a global computer network featuring information in the fields of health and health information regarding cancer, cancer treatment, recovery and survival; medical evaluation and diagnosis of cancer; medical analysis for cancer diagnosis and prognosis based on DNA and RNA screening; medical services for the diagnosis of conditions of the human body; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing a website via a global computer network featuring information regarding the medical diagnosis and treatment of dermatology, oncology, hematology, and for gastroenterological disorders; providing medical information, consultancy and advisory services; providing links to the websites of others featuring information about the diagnosis and treatment of cancer |
| Disclaimer with Predetermined Text | "ONCOLOGY" |
| Goods and Services | Development of pharmaceutical preparations and medicines; drug discovery services; pharmaceutical drug development services; research relating to medicines; medical research; pharmaceutical research and development services; medical research services in the field of cancer; research and development of biological and chemical preparations for the treatment of blood diseases, bone and bone marrow diseases, and cancer; research and development of pharmaceutical products, preparations and compounds for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; research and development of pharmaceutical preparations for use in dermatology, oncology, hematology, and for gastroenterological disorders; scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials regarding pharmaceutical preparations and drugs in the field of blood diseases, and cancers; DNA screening and analysis services for scientific research purposes |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 24, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 24, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 24, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | SIERRA ONCOLOGY LLC |
| Party Type | 21 - New Owner After Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | WILMINGTON, DE 19808 |
| Party Name | Sierra Oncology, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94404 |
| Party Name | Sierra Oncology, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94404 |
| Event Date | Event Description |
| Monday, March 4, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, March 4, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, August 2, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, July 31, 2023 | SOU EXTENSION 1 GRANTED |
| Monday, July 31, 2023 | SOU EXTENSION 1 FILED |
| Monday, July 31, 2023 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, February 8, 2023 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, January 31, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, December 6, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 6, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, November 16, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, October 31, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, October 21, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, October 20, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, October 20, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 12, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, October 12, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, October 12, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, April 21, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, April 21, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, April 21, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 20, 2022 | ASSIGNED TO EXAMINER |
| Friday, September 24, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, July 29, 2021 | NEW APPLICATION ENTERED |